BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 28531902)

  • 1. Evaluation of Prostate Imaging Reporting and Data System Classification in the Prediction of Tumor Aggressiveness in Targeted Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy.
    Borkowetz A; Platzek I; Toma M; Renner T; Herout R; Baunacke M; Laniado M; Baretton GB; Froehner M; Zastrow S; Wirth MP
    Urol Int; 2017; 99(2):177-185. PubMed ID: 28531902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective comparison of transperineal magnetic resonance imaging/ultrasonography fusion biopsy and transrectal systematic biopsy in biopsy-naïve patients.
    Borkowetz A; Hadaschik B; Platzek I; Toma M; Torsev G; Renner T; Herout R; Baunacke M; Laniado M; Baretton G; Radtke JP; Kesch C; Hohenfellner M; Froehner M; Schlemmer HP; Wirth M; Zastrow S
    BJU Int; 2018 Jan; 121(1):53-60. PubMed ID: 28921850
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy in Patients with Low-Risk Prostate Cancer Under Active Surveillance Undergoing Surveillance Biopsy.
    Borkowetz A; Renner T; Platzek I; Toma M; Herout R; Baunacke M; Groeben C; Huber J; Laniado M; Baretton GB; Froehner M; Zastrow S; Wirth MP
    Urol Int; 2018; 100(2):155-163. PubMed ID: 29339663
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of Transperineal Magnetic Resonance Imaging/Ultrasound-Fusion Biopsy Compared to Transrectal Systematic Biopsy in the Prediction of Tumour Aggressiveness in Patients with Previously Negative Biopsy.
    Borkowetz A; Renner T; Platzek I; Toma M; Herout R; Baunacke M; Groeben C; Huber J; Laniado M; Baretton G; Froehner M; Zastrow S; Wirth MP
    Urol Int; 2019; 102(1):20-26. PubMed ID: 30149386
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Prospective Comparison of Selective Multiparametric Magnetic Resonance Imaging Fusion-Targeted and Systematic Transrectal Ultrasound-Guided Biopsies for Detecting Prostate Cancer in Men Undergoing Repeated Biopsies.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Thomsen HS
    Urol Int; 2017; 99(4):384-391. PubMed ID: 28651247
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospective Evaluation of the Prostate Imaging Reporting and Data System Version 2 for Prostate Cancer Detection.
    Mertan FV; Greer MD; Shih JH; George AK; Kongnyuy M; Muthigi A; Merino MJ; Wood BJ; Pinto PA; Choyke PL; Turkbey B
    J Urol; 2016 Sep; 196(3):690-6. PubMed ID: 27101772
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prostate cancer detection on transrectal ultrasonography-guided random biopsy despite negative real-time magnetic resonance imaging/ultrasonography fusion-guided targeted biopsy: reasons for targeted biopsy failure.
    Cash H; Günzel K; Maxeiner A; Stephan C; Fischer T; Durmus T; Miller K; Asbach P; Haas M; Kempkensteffen C
    BJU Int; 2016 Jul; 118(1):35-43. PubMed ID: 26384851
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The detection of significant prostate cancer is correlated with the Prostate Imaging Reporting and Data System (PI-RADS) in MRI/transrectal ultrasound fusion biopsy.
    Cash H; Maxeiner A; Stephan C; Fischer T; Durmus T; Holzmann J; Asbach P; Haas M; Hinz S; Neymeyer J; Miller K; Günzel K; Kempkensteffen C
    World J Urol; 2016 Apr; 34(4):525-32. PubMed ID: 26293117
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeted MRI/TRUS fusion-guided biopsy in men with previous prostate biopsies using a novel registration software and multiparametric MRI PI-RADS scores: first results.
    Tewes S; Hueper K; Hartung D; Imkamp F; Herrmann TR; Weidemann J; Renckly S; Kuczyk MA; Wacker F; Peters I
    World J Urol; 2015 Nov; 33(11):1707-14. PubMed ID: 25774003
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison between target magnetic resonance imaging (MRI) in-gantry and cognitively directed transperineal or transrectal-guided prostate biopsies for Prostate Imaging-Reporting and Data System (PI-RADS) 3-5 MRI lesions.
    Yaxley AJ; Yaxley JW; Thangasamy IA; Ballard E; Pokorny MR
    BJU Int; 2017 Nov; 120 Suppl 3():43-50. PubMed ID: 28749035
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluating the performance of PI-RADS v2 in the non-academic setting.
    Jordan EJ; Fiske C; Zagoria RJ; Westphalen AC
    Abdom Radiol (NY); 2017 Nov; 42(11):2725-2731. PubMed ID: 28451763
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A cohort of transperineal electromagnetically tracked magnetic resonance imaging/ultrasonography fusion-guided biopsy: assessing the impact of inter-reader variability on cancer detection.
    Wajswol E; Winoker JS; Anastos H; Falagario U; Okhawere K; Martini A; Treacy PJ; Voutsinas N; Knauer CJ; Sfakianos JP; Lewis SC; Taouli BA; Rastinehad AR
    BJU Int; 2020 Apr; 125(4):531-540. PubMed ID: 31762182
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Value of three biopsy methods in prostate cancer detection: a meta-analysis and systematic review.
    Deng YS; He YH; Ying WW; Liu HL; Li PZ; Ma CY; Ding ZS; Chen X; Wang JF; Zhou XF
    Eur Rev Med Pharmacol Sci; 2021 Mar; 25(5):2221-2234. PubMed ID: 33755960
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of histological findings obtained combining US/mp-MRI fusion-guided biopsies with systematic US biopsies: mp-MRI role in prostate cancer detection and false negative.
    Faiella E; Santucci D; Greco F; Frauenfelder G; Giacobbe V; Muto G; Zobel BB; Grasso RF
    Radiol Med; 2018 Feb; 123(2):143-152. PubMed ID: 29019021
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PI-RADS Version 2 Category on 3 Tesla Multiparametric Prostate Magnetic Resonance Imaging Predicts Oncologic Outcomes in Gleason 3 + 4 Prostate Cancer on Biopsy.
    Faiena I; Salmasi A; Mendhiratta N; Markovic D; Ahuja P; Hsu W; Elashoff DA; Raman SS; Reiter RE
    J Urol; 2019 Jan; 201(1):91-97. PubMed ID: 30142318
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship Between Prebiopsy Multiparametric Magnetic Resonance Imaging (MRI), Biopsy Indication, and MRI-ultrasound Fusion-targeted Prostate Biopsy Outcomes.
    Meng X; Rosenkrantz AB; Mendhiratta N; Fenstermaker M; Huang R; Wysock JS; Bjurlin MA; Marshall S; Deng FM; Zhou M; Melamed J; Huang WC; Lepor H; Taneja SS
    Eur Urol; 2016 Mar; 69(3):512-7. PubMed ID: 26112001
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Added Value of Multiparametric Ultrasonography in Magnetic Resonance Imaging and Ultrasonography Fusion-guided Biopsy of the Prostate in Patients With Suspicion for Prostate Cancer.
    Maxeiner A; Stephan C; Durmus T; Slowinski T; Cash H; Fischer T
    Urology; 2015 Jul; 86(1):108-14. PubMed ID: 26142593
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Can Prostate Imaging Reporting and Data System Version 2 reduce unnecessary prostate biopsies in men with PSA levels of 4-10 ng/ml?
    Xu N; Wu YP; Chen DN; Ke ZB; Cai H; Wei Y; Zheng QS; Huang JB; Li XD; Xue XY
    J Cancer Res Clin Oncol; 2018 May; 144(5):987-995. PubMed ID: 29504080
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparison of PI-RADS v1 and v2 for multiparametric MRI detection of prostate cancer with whole-mount histological workup as reference standard.
    Schaudinn A; Gawlitza J; Mucha S; Linder N; Franz T; Horn LC; Kahn T; Busse H
    Eur J Radiol; 2019 Jul; 116():180-185. PubMed ID: 31153562
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.